Associated Papers
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
35304574 (PubMed )
Supplement: 41388_2022_2263_MOESM5_ESM.xlsx › Supplementary_Table_4
Development and validation of a targeted gene sequencing panel for application to disparate cancers.
McCabe MJ et al.
Scientific Reports, 2019
31745186 (PubMed )
Supplement: 41598_2019_52000_MOESM2_ESM.xlsx › Sheet1
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
31034466 (PubMed )
Supplement: pcbi.1006981.s010.xlsx › final_benchmark
Mobile Genome Express (MGE): A comprehensive automatic genetic analyses pipeline with a mobile device.
Yoon JH et al.
Plos One, 2017
Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
Anoosha P et al.
Mutation Research, 2015
Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.
Williams MD et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2010
Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy.
Kancha RK et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Select a paper to view details